UC 38

Drug Profile

UC 38

Alternative Names: NSC 629243

Latest Information Update: 11 Sep 1996

Price : $50

At a glance

  • Originator Uniroyal Chemical
  • Developer National Cancer Institute (USA)
  • Class Antiretrovirals; Benzoic acids
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 11 Sep 1996 Discontinued-Preclinical for HIV-1 infections in USA (PO)
  • 01 Mar 1996 A preclinical study has been added to the pharmacokinetics section
  • 02 May 1995 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top